{"prompt": "['APPENDIX 6 : RECIST CRITERIA, VERSION 1.1', '\"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)\" E.A. Eisenhauer, P. Therasse,', 'J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar,', 'L. Dodd, R. Kaplan, D. Lacombe, J. Verweij;', 'Eur J Cancer, 45 (2009) 228-247.', 'Lesions on inclusion:', 'Lesions and lymph nodes are classed individually as being measurable or non-measurable.', 'Measurable disease', 'A lesion is measurable if it can be accurately measured in at least one dimension (longest diameter in the plane of', 'measurement is to be reported).', 'To be measurable, lesions must have a minimum size of', '> 10 mm on CT (CT scan slice thickness no greater than 5 mm)', '> 10 mm on clinical examination (measured using a caliper); lesions that cannot be accurately measured with calipers', 'should be classed as non-measurable', '20 mm on chest X-ray', 'For a malignant lymph node to be considered pathological and measurable, its short axis must measure 15 mm (the short', 'axis is the axis perpendicular to the largest dimension of the lymph node). Only the length of this short axis is reported on', 'inclusion and during follow-up.', 'Non-measurable disease', 'All other lesions, including small lesions (longest diameter < 10 mm on CT or lymph nodes with > 10 mm and < 15 mm', 'short axis) as well as truly non-measurable lesions: leptomeningeal disease, ascites, pleural or pericardial effusion,', 'inflammatory breast disease, lymphangitic involvement of skin or lung, abdominal masses identified by physical', 'examination but unconfirmed by imaging techniques, and cystic lesions.', 'NB: bone lesions, simple cystic lesions and lesions that have received prior local treatment require special consideration', '(see comments below).', 'Target lesions', 'Target lesions are selected from the measurable lesions presented by the patient on entry into the study. A maximum of five', 'target lesions are selected, with no more than two target lesions per organ. Target lesions will be selected so as to be', 'representative of all involved organs. The largest lesions (in the longest dimension) that may be repeatedly and reproducibly', 'measured throughout the trial using the initial examination method are to be chosen. Lymph nodes may be considered as', 'target lesions if their short axis as measured on CT is 15 mm.', 'The sum of the diameters of these target lesions (the longest diameter for lesions, and short axis for lymph nodes) is what', 'is', 'followed throughout the trial for assessing response or progression.', 'Non-target lesions', 'All other lesions are identified as non-target lesions and are also recorded on inclusion. They are not measured but they are', 'followed throughout the trial.', 'Criteria for response to treatment:', 'Target lesions:', 'Complete response (CR) Disappearance of all lesions, and all lymph nodes (whether target or non-target) must have', 'reduction in short axis to < 10 mm.', 'Note: lymph nodes selected as target lesions must always be measured (in the same anatomical plane as the baseline', 'examination), even if they decrease in size during the study to a short axis of < 10 mm. Therefore, when lymph nodes are', \"used as target lesions, the sum of the lesions' dimensions is not necessarily zero even if there is CR since a normal lymph\", 'node is defined as having a short axis < 10 mm. To qualify, for CR, every lymph node must achieve a short axis of < 10 mm.', 'Partial response (PR) At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline', 'sum diameters.', 'Progressive disease (PD) At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest', 'sum, or nadir, in the study (this includes the baseline sum if that is the smallest in the study). In addition to the relative', 'increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.', 'Note: the appearance of one or more new lesions is also considered progression.', 'However, if there is progression compared with the nadir and response compared with the baseline examination, this', 'is', 'considered progression.', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 83 de 123']['Stable disease (SD) Neither PR, CR or PD.', 'Non-target lesions', 'CR Disappearance of all non-target lesions and normalization of tumor markers. All lymph nodes must have reached a short', 'axis of < 10 mm.', 'Non-CR/SD Persistence of one or more non-target lesions and/or tumor marker levels above the normal limits.', 'PD Unequivocal increase in size of existing non-target lesions or appearance of one or more new lesions.', 'Overall response:', 'Target lesions', 'Non-target lesions', 'New lesion', 'Overall response', 'CR', 'CR', 'No', '=', 'CR', 'CR', 'Non-CR/Non-PD', 'No', '=', 'PR', 'CR', 'Not assessed', 'No', '=', 'PR', 'PR', 'Non-PD or not all assessed', 'No', '=', 'PR', 'SD', 'Non-PD or not all assessed', 'No', '=', 'SD', 'Not all assessed', 'Non-PD', 'No', '=', 'Unassessable', 'PD', 'Any', 'Yes or no', '=', 'PD', 'Any', 'PD', 'Yes or no', '=', 'PD', 'Any', 'Any', 'Yes', '=', 'PD', 'Comments on lesion measurability on entry', 'Bone lesions:', 'Bone scan, PET scan or plain films are not considered adequate imaging techniques to measure bone lesions. However,', 'these techniques can be used to confirm the presence or disappearance of bone lesions.', 'Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components, can be considered as measurable', 'lesions if they can be evaluated by cross-sectional imaging techniques such as CT or MRI and if the soft tissue component', 'meets the definition of measurability described above.', 'Cystic lesions:', 'Lesions that meet the criteria for radiographically defined simple cysts are not considered as malignant lesions (be it', 'measurable or non-measurable).', 'Cystic lesions thought to represent cystic metastases can be considered as measurable lesions if they meet the definition of', 'measurability described above. However, if noncystic lesions are present in the same patient, these are preferred for', 'selection as target lesions.', 'Lesions with prior local treatment:', 'Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, are usually not', 'considered measurable unless there has been demonstrated progression in the lesion since the local therapy. Study protocols', 'should detail the conditions under which such lesions may be considered measurable.', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 84 de 123']\n\n###\n\n", "completion": "END"}